An editorial reading of the Thymosin Beta-4 record. Not a clinic. Not a vendor.

Who we are

TB-500 Doctor is an independent editorial project that publishes summaries of the peer-reviewed research literature on TB-500 and the parent Thymosin Beta-4 peptide. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The 'doctor' modifier in the domain name is editorial framing — a position the publisher occupies relative to the research literature, not a claim about the site's services. There is no clinical practice behind this URL. There are no patients, no consultations, no prescriptions, no products. The framing is curatorial: we read the research record on TB-500 and write about what is there, what is not there, and where the most-cited claims diverge from what the studies actually measured.

What we publish, and how

Each page on this site is structured around a single editorial question — what TB-500 is, what it does in the research record, how it has been dosed in published studies, what the clinical trial program for the parent peptide has shown, and what the open questions still are.

Our sourcing is restricted to peer-reviewed primary literature (PubMed, PMC, peer-reviewed journals), registered clinical trials (ClinicalTrials.gov, EU CTR), and regulator-grade documentation (FDA labels, WADA Prohibited List). Vendor pages, supplement-industry whitepapers, and forum posts are not sources. Where vendor-circulated claims appear — the 'two- to three-hour half-life' figure for the 7-AA fragment, for example — we flag them as vendor-origin and note the absence of peer-reviewed support.

The Block Frame visual treatment is part of the editorial method. Every claim sits inside a labeled bordered block. Categories are color-coded: pink for molecular mechanism, sky blue for clinical trial results, lime for preclinical animal-model data, gold for regulatory and WADA status. The framing is the disclosure — readers can see at a glance which kind of evidence a given block represents.

What we do not do

We do not provide medical advice. We do not recommend doses for human use. We do not sell, distribute, or recommend specific vendors of TB-500 or any other peptide. We do not have a clinical team, a pharmacist on staff, an MD on staff, or any in-person presence. We do not have a physical clinic location.

Where our writing describes published research doses (the 5-microgram topical dose in the Sosne corneal alkali-burn study, the 150-microgram intraperitoneal regimen in the Smart epicardial study, the 1,260 mg IV dose in the Ruff Phase I trial), those numbers are reported as research-context only — they describe what investigators administered to rats, mice, pigs, or healthy adult volunteers under research protocols. They are not human therapeutic recommendations and they are not extrapolatable to underground or non-clinical use.

Regulatory context

TB-500 is not approved by the FDA, EMA, MHRA, TGA, PMDA, or any other major regulator for any human indication. The 43-AA parent peptide has reached Phase III in ophthalmic indications and Phase II in cardiac indications without yet receiving marketing authorization.

TB-500 is prohibited at all times under the World Anti-Doping Code, listed under sections S2 and S0 of the Prohibited List. Equine doping-control laboratories have validated LC-MS detection of TB-500 in plasma and urine after intravenous administration, and the analytical infrastructure to enforce the ban exists in human anti-doping practice.